Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project by Majumdar, Suvankar et al.
OR I G I N A L A R T I C L E
Parvovirus B19 infection in sickle cell disease: An analysis
from the Centers for Disease Control haemoglobinopathy
blood surveillance project
Suvankar Majumdar1,2 | Christopher J. Bean3 | Christine De Staercke3 |
James Bost1 | Robert Nickel1 | Thomas Coates4 | Andrew Campbell1,5 |
Alexis Thompson6
1Children's National Medical Center, George
Washington University School of Medicine &
Health Sciences, Washington, DC
2Department of Pediatrics, University of
Mississippi Medical Center, Jackson,
Mississippi
3Division of Blood Disorders, National Center
on Birth Defects and Developmental
Disabilities, Centers for Disease Control and
Prevention, Atlanta, Georgia
4Division of Hematology, Children's Hospital
Los Angeles, Los Angeles, California
5Department of Pediatrics, University of
Michigan, Ann Arbor, Michigan
6Feinberg School of Medicine, Northwestern
University, Chicago, Illinois
Correspondence
Suvankar Majumdar, Division of Hematology,
Center for Cancer & Blood Disorders,
Children's National Medical Center, George
Washington University School of Medicine &




National Center on Birth Defects and
Developmental Disabilities, Grant/Award
Number: U1U50DD000879; Centers for
Disease Control and Prevention
Summary
Objective: In the multicentre Haemoglobinopathy Blood Surveillance Project, to eval-
uate the seroprevalence of parvovirus B19 and DNA viral load in sickle cell dis-
ease (SCD).
Background: Although the epidemiology of parvovirus B19 seropositivity in SCD has
been well documented, there are few studies that have assessed possible persistent
parvovirus DNAemia and associated risk factors including blood transfusion.
Methods: A qualitative analysis of parvovirus B19 serology using ELISA and quantita-
tive parvovirus B19 DNA by RT-PCR was performed in patients with SCD.
Results: Of 322 patients, 113 (35%) were parvovirus IgG positive and 119 (37%)
were IgM positive at enrolment. The prevalence of IgG positivity increased with age.
71/322 (22%) were parvovirus DNA positive at enrolment with a mean viral load of
15 227 ± 55 227 SD. (range 72-329 238 IU/mL). Patients who were positive for par-
vovirus B19 DNA received a significantly higher red blood cell transfusion volume in
the prior year compared to patients who were negative (mean RBC volume = 8310 mL
vs 5435 mL, respectively; P = .0073). Seventy-seven patients had follow-up testing
approximately 1 year after enrolment and 11/28 (39%) patients had persistently
positive IgM.
Conclusion: Further studies are needed to better understand the natural history of
parvovirus B19 infection in SCD especially in relation to RBC transfusion as a risk
factor, as well as disease outcome and severity.
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1 | BACKGROUND
Sickle cell disease (SCD) is an autosomal recessive red blood cell disor-
der that occurs from a single base mutation in the beta globin gene,
which leads to the production of abnormal haemoglobin (haemoglobin
S) and sickling of red blood cells. The homozygous form of the
disorder, haemoglobin SS, and other compound heterozygotes such as
haemoglobin SC, haemoglobin Sβ thalassemia, of different genotypes
are collectively known as SCD. Human parvovirus B19 infection is a
common childhood infection that may be associated with life-
threatening anaemia from transient aplastic crisis (TAC) in individuals
with SCD. The virus is trophic for erythroid precursors in the bone
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marrow and is able to shut down red blood production, thus accentu-
ating the severity of anaemia. In the United States, there is a high
(≈30%-50%) serologic prevalence of previous parvovirus B19 infec-
tion in children with SCD, with seroconversion rates that increase
with age.1-3 However, interestingly, Zimmerman et al. found that only
27% of patients with sickle cell anaemia and who were seropositive
for parvovirus B19 had a clinically recognised TAC, suggesting that
many acquire parvovirus without developing severe symptoms of
TAC.3 In a cross-sectional study, Makhlouf et al showed that parvovi-
rus B19 DNAemia appears to be common in SCD. Among
64 haemoglobin SS (sickle cell anaemia) and 36 haemoglobin AS
(sickle cell trait) children with IgG positive titers, 24 had evidence of
parvovirus B19 DNA as detected by polymerase chain reaction
(PCR).4 Patients with viremia were reported to have a lower baseline
haemoglobin than those with a previous history of parvovirus B19
infection denoted by serological markers but no active viremia.4
Although the epidemiology of parvovirus B19 seropositivity in
SCD has been well documented, there are few studies that have
assessed the presence of persistent DNAemia and if there is an asso-
ciation to RBC transfusion.1-6 Persistent parvovirus B19 DNAemia
has been described mainly in immunocompromised hosts with leukae-
mia and bone marrow/organ transplantation.7-9 Further, tntravenous
immunoglobulin has been reported to eradicate the virus in immuno-
compromised hosts.10,11 Hydroxyurea is a commonly prescribed medi-
cation for SCD that increases haemoglobin F production and thereby
decreases red blood cell haemolysis, but it also has significant effects
on many immune cell counts.12 Although hydroxyurea has been
shown to attenuate the severity of TAC without affecting the durable
serologic response to parvovirus B19,1 it is unknown if hydroxyurea
therapy is associated with a decrease of parvovirus B19 DNAemia in
patients with SCD.
The overall goal of the Centers for Disease Control (CDC) multi-
centre study on Blood Safety Surveillance among People with Blood
Disorders was to obtain a better understanding of blood transfusion
related complications in haemoglobin disorders, for example, rates of
allo-immunisation, allergic reactions, burden of emerging pathogens
etc. Using stored plasma samples, the primary objective of this study
was to evaluate the seroprevalence of parvovirus B19 and the DNA
viral load in individuals with SCD, and to assess for potential risk fac-
tors such as transfusion and hydroxyurea for persistent parvovirus
B19 DNAemia in this high-risk population.
2 | METHODS
A total of 322 paediatric patients diagnosed with SCD were enrolled
in this study. Plasma was obtained at enrolment, and if available,
approximately 1 year later. Plasma samples were stored at −80C until
antibody testing and viral DNA extraction. Demographic information,
diagnosis, red blood cell transfusion history in the past year (number
and volume of packed red blood cell), hydroxyurea use, and history of
splenectomy were collected at enrolment. The qualitative analysis of
human parvovirus B19 antibody IgG and human parvovirus B19
antibody IgM of study plasma samples was conducted at the CDC
using MyBioSource Human parvovirus B19 IgG and IgM ELISA kit
(Solid phase enzyme-linked immunosorbent assay; Cat#
MBS9304327 and MBS9301249). Plasma samples were diluted
5-fold and assayed in duplicates. Positive and negative control sam-
ples were used to determine the cut off values. Purified Viral parvovi-
rus B19 DNA was extracted from the same plasma sample aliquots
using the ZR Viral DNA Kit (The Epigenetics Company—ZYMO
RESEARCH Corp [Cat# D3016]). Denaturation of viral DNA and
recovery of DNA was accomplished using the unique ZR Viral DNA
Buffer and individual Zymo-Spin IC columns. DNA was eluted with
15 μL of elution buffer (DNA recovery up to 1.2-2.3 μg total DNA)
and assayed in downstream RT-PCR application with the RealStar Par-
vovirus B19 PCR Kit 1.0 from Altona Diagnostics (Hamburg, Ger-
many).13 The quantification standards contained standardised
concentrations of parvovirus B19-specific DNA. These quantification
standards were calibrated against the second WHO International
Standard for Parvovirus B19 for Nucleic Acid Amplification Tech-
niques (NIBSC code: 99/802) and used to generate a Standard Curve
(10 000-0.625 IU/μL).14 Viral loads in study samples were calculated
as the product of eluate volume (15 μL) and eluate viral load divided
by the volume of sample input (0.2 mL) and were reported in
IU/mL. The limit of detection (LOD) corresponds to 68 IU/mL and
was defined as the LOD in the tested eluate of parvovirus
B19-specific DNA that can be detected: 0.41 IU/μL [95% confidence
interval (CI): 0.27-0.90 IU/μL]. A conservative cutoff value greater
than 0.90 IU/ μL in the eluate was used as the threshold for positivity.
2.1 | Statistical methods
Descriptive statistics were provided as mean and SD and/or as
median and the IQR (interquartile range). Comparisons of two cate-
gorical variables were done using chi-squared test. Comparing of con-
tinuous outcomes to categorical predictors were done using t tests if
the samples were large enough (transformations were done to verify
significance remained at 0.05 if data were skewed). The Wilcoxon
signed-rank test was used to assess the relationship between parvovi-
rus IgG positivity and RBC transfusions.
3 | RESULTS
A total of 322 participants had SCD and parvovirus B19 testing with
the following genotypes: haemoglobin SS (n = 291), haemoglobin SC
(n = 15), haemoglobin S/β0 thalassemia (n = 9), haemoglobin Sβ+ thal-
assemia (n = 6), and other compound heterozygous form of SCD
(n = 1). The F:M ratio was 0.9:1 with a mean age of 14.1 years
±9.6 SD (range 1-58 years). 113 (≈35%) had a history of hydroxyurea
use and 25 (≈8%) had a history of splenectomy. All participants were
tested and found to be negative for HIV.
At enrolment, 113/322 (35%) were IgG positive. 144/322 (45%)
patients had never been infected with parvovirus B19 infection
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(Table 1). Overall, the IgG seroprevalence increased with age: 28%
(0-5 years), 32% (>5-10 years), 35% (>10-15 years), 30%
(>15-20 years), and 48% (>20 years).
There were 119/322 (37%) SCD patients who were IgM positive.
Of those IgM positive, 41 (34%) had quantifiable parvovirus B19 DNA
indicative of recent active infection. In the enrolment samples, 22%
(71/322) of patients had a positive parvovirus PCR regardless of their
enrolment serology status, with a mean viral load 15 227 ± 55 227
SD. (range 72-329 238 IU/mL). There was no significant difference
in parvovirus B19 DNA viral load with respect to hydroxyurea use
(P = .999), history of splenectomy (P = .999), or age (P = .162). 58/322
(18%) had no history of red blood cell transfusion in the prior year.
Of 264 subjects who received a red blood cell transfusion, the
mean ± SD volume transfused in the prior year was 6338 ± 7060 mL.
There was a significant difference in DNA viral load between individ-
uals who received a RBC transfusion vs those who did not receive a
transfusion (mean viral load 4214 IU/mL vs 188 IU/mL respec-
tively; P = .034).
A total of 86/322 (27%) participants had a history of stroke as an
indication for chronic RBC transfusion, and 39 subjects had received
at least one erythrocytopharesis (red blood cell exchange transfusion)
in the prior year. Patients who were positive for parvovirus B19 DNA
received a significantly higher red blood cell transfusion volume in the
prior year compared to patients who were negative (mean RBC vol-
ume = 8310 mL vs 5435 mL respectively; P = .0073).
Seventy-seven patients had a second sample collected approxi-
mately 1 year after the first sample (Table 2). In this cohort, 2/14 sub-
jects that were initially PCR positive had remained DNAemic in the
second year of testing, with a mean viral load at enrolment and follow
up of 169 IU/mL and 139 IU/mL, respectively. Antibody status for
these 14 subjects showed 3/14 were IgG positive and 8/14 were IgM
positive at enrolment. As noted in Tables 1, 21/322 (6.5%) were par-
vovirus B19 DNA positive but negative for IgM and IgG at enrolment.
Of those 21 subjects, five had follow-up testing of which four became
parvovirus B19 DNA negative and one continued to be positive.
11/28 (39%) patients with a positive IgM at enrolment had persis-
tently positive IgM on repeat testing with 7/11 of these patients
being parvovirus PCR negative at both time points and 4/11 of these
patients changing from PCR positive to negative suggesting that posi-
tive IgM titers may continue for at least 1 year from infection
(Table 2). 14/21 who were IgG positive at enrolment remained parvo-
virus IgG positive and there was no association with history of RBC
transfusion in the past year (P = .5001).
TABLE 1 Parvovirus B19 IgM, IgG and DNA viral load in 322 patients with sickle cell disease at enrolment
Interpretation IgM IgG PCR Viral load; mean (SD) IU/mL; median (IQR) IU/mL N
Never infected Neg Neg Neg 3.1 (11.3) 144
0 (0–0)
Old infection, cleared Neg Pos Neg 13.5 (21.5) 29
0 (0-31.0)
Recent infection, cleared Pos Pos Neg 10.5 (18.8) 54
0 (0-20.3)
Recent infection, cleared Pos Neg Neg 9.1 (17.8) 24
0 (0-4.0)
Early recent infection, active Neg Neg Pos 17 054.3 (71 632.0) 21
162.1 (95.95.3-685.4)
Recent infection, active Pos Pos Pos 7595.2 (25 672.3) 21
540.6 (119.6-1363.5)
Recent infection, active Pos Neg Pos 22 758.2 (67 814.8) 20
174.7 (106.5-802.2)
Chronic infection Neg Pos Pos 12 037.4 (32 004.2) 9
588.8 (199.4-1396.6)
Note: The cutoff for PCR positivity was >0.90 IU/μL in the tested eluate or a viral load in the original sample of >68.00 IU/mL.
TABLE 2 Demographic and parvovirus serology in 77 subjects





Haemoglobin Sβ thalassemia 1
Haemoglobin Sβ+ thalassemia 1
Age (mean ± SD) 13.2 ± 6.9 years
Gender (female) 34 (44%)
Proportion that stayed IgG positive 14/21 (67%)
Proportion that stayed IgM positive 11/28 (39%)
Proportion that stayed PCR positive 2/14 (14%)
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4 | DISCUSSION
Our study shows that the presence of parvovirus B19 DNAemia in
SCD is related to red blood cell transfusion history. Patients with par-
vovirus B19 DNAemia may have received more RBC transfusions
because of their parvovirus infection causing anaemia. Alternatively, it
is possible that RBC transfusions may transmit parvovirus B19 DNA.
A study in blood donors showed that positive detection of parvovirus
B19 DNA approximately 6 months after acute infection can be due to
the presence of remnant DNA strands and not infectious virions.15
Furthermore, the potential transmission of parvovirus via blood prod-
ucts has been previously reported. In a study of 75 parvovirus, B19
infected blood donors, DNA persisted for a mean of 21.5 months.16
Significantly, parvovirus B19 transmission by cellular blood products
has been found to correlate with viral concentration. In a study from
Germany, parvovirus DNA was detected in 9 of 19 recipients of
red blood cells from donors who had a viral load of greater than
105 IU/mL, whereas none of the of 16 recipients of RBCs from those
with less than 105 IU/mL were positive for parvovirus B19 DNA.16
In a linked donor -recipient study to evaluate parvovirus B19 trans-
mission by blood component transfusion, no transmission to 24 sus-
ceptible recipients from transfusion of components with B19 DNA at
concentrations less than 106 IU/mL (upper 95% confidence interval,
11.7%) was found.17 Also, of 105 DNA-positive donations and
112 positive components transfused to 107 distinct recipients, no
clinical disease related to parvovirus B19 was observed, although it is
difficult to draw the same predication of a benign clinical course in
patients with SCD who are known to be high risk of a more severe
clinical course because of their underlying haemolytic anaemia.
Indications for red blood cell transfusions in SCD include history of
acute stroke for which patients are often placed on lifelong monthly
RBC transfusions to prevent stroke recurrence (secondary prophylaxis).
Some patients may receive long-term erythrocytopharesis, which
involves exposure to large amounts of red blood cells. Other indications
for intermittent red blood cell transfusion are related to disease severity
such as acute chest syndrome (a common lung complication in SCD)
and severe anaemia from acute parvovirus B19 infection or hyper-
haemolysis. Parvovirus B19V DNA is detectable in 0.5% to 0.9% of
blood donations, with most showing relatively low DNA concentrations
(<100-1000 IU/mL). Furthermore, it is unclear from our results if trans-
fusions caused the observed increased DNAemia, or if this DNAemia
resulted in any clinical consequences. We found that only a small pro-
portion of individuals with SCD (<3%) have remained parvovirus
DNAemic with relatively low levels of DNA. Persistent parvovirus DNA
has been reported in immunocompromised hosts. However, our cohort
of 322 subjects were tested and found not to be immuosuppressed
from HIV infection although other medical conditions associated with
immune suppression could not be excluded. Overall, our results suggest
that a cautious approach would be to perform blood donor screening
for parvovirus B19 with an appropriately set cutoff infectivity for
“parvovirus safe” red blood cells in this high-risk population receiving
blood transfusion. In addition, continued efforts should be placed on
the development of candidate vaccines against parvovirus B19,
especially due to the risk of increased morbidity in SCD.18 The risk to
this approach may be to further complicate finding extended antigen-
matched RBCs for SCD patients to prevent alloimmunization, which is
supported as standard of care.19
Importantly, we did not find an association with parvovirus DNA
viral load and hydroxyurea use despite its known effects on the
immune system and risk of neutropenia. This finding is consistent with
the results from controlled clinical trials in SCD, which have found
that hydroxyruea does not increase the general risk of infection.20,21
Previous reports in the general population have shown that par-
vovirus may persist but the implications in SCD of continued parvovi-
rus DNAemia are unknown. Notably, in the general population, recent
parvovirus infection—with B19 DNA detected by PCR, and IgG and
IgM positivity—as well as persistent infection with undetectable IgM,
have been linked to pro-inflammatory cytokines and chronic arthritis/
arthropathy8,22,23; and it is unknown if this contributes towards the
process of vaso-occlusion in SCD leading to organ damage. Interest-
ingly, a history of parvovirus B19 infection has been shown to be
associated with silent cerebral infarcts in SCD. In a retrospective
cross-sectional cohort study design in 958 sickle cell participants who
underwent brain magnetic resonance imaging, silent cerebral infarct
was present in 30% of participants and 17% had a history of a parvo-
virus B19 infection.24
Our findings of increasing seroprevalence rates of Ig G positivity
with age are consistent with other previously reported studies in the
United States.1-3 The serology and PCR results suggest that many
patients across all age groups have never been infected with parvovi-
rus B19, although interpretation may be difficult as some patients
may lose their Ig G positivity over time. Also, the 21 subjects who
were parvovirus B19 PCR positive but Ig M/Ig G negative suggests
early recent infection or possibly the acquisition of parvovirus via
blood transfusion. While IgM titers typically peak at 3 to 4 weeks
from onset of infection, our study shows that the IgM titers may
remain positive over a longer period of time in SCD. Although this
could indicate re-infection or viral persistence, durability of positive
IgM titers over a long period of time has been reported in other
conditions.25
A limitation to our study is that no information was collected on a
prior clinical TAC event or the timing of the most recent transfusion in
relation to sample collection and thus only one total year of blood
transfusion volume was assessed. In addition, information on complete
blood counts was not obtained which would determine if the presence
of persistent parvovirus B19 DNAemia affects the degree or severity of
anaemia in SCD. Nonetheless, based on appropriate cuff off for infec-
tivity, “parvovirus safe” red cells could be supplied to this high-risk pop-
ulation receiving blood transfusion as a measure of safety. Further
studies are needed to better understand the natural history of parvovi-
rus B19 infection in SCD especially in relation to RBC transfusion and
any association with disease outcome and severity.
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